Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON25483
NL-OMON25483
Recruiting
Not Applicable

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers duringthe perioperative period: to withdraw or to continue? A multicenter randomized controlled trial.

niversity Medical Center Utrecht, The Netherlands0 sites3,200 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-cardiac major surgery

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
on-cardiac major surgery
Sponsor
niversity Medical Center Utrecht, The Netherlands
Enrollment
3200
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
niversity Medical Center Utrecht, The Netherlands

Eligibility Criteria

Inclusion Criteria

  • •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • •\-Chronic ACEI or ARB use for the treatment of hypertension. Patients who use a com\-bination pill with a diuretic are eligible as well;
  • •\-Scheduled for elective intermediate to high risk noncardiac surgery, defined according to the European Society of Cardiology / European Society of Anesthesiology guidelines on noncardiac surgery;
  • •\-Expected postoperative length of stay of at least two days.

Exclusion Criteria

  • •A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • •\-Severe chronic kidney disease, defined as GFR\<30 ml/min/1\.73 m2;
  • •\-ACEI/ARB use for the treatment of chronic systolic heart failure, defined as left ven\-tricular ejection fraction \=40%;
  • •\-ACEI/ARB use within one year after ST\-elevated myocardial infarction, according to the fourth universal definition of myocardial infarction;
  • •\-Transplant surgery;
  • •\-ACEI/ARB use in a combination pill together with a drug other than a diuretic, including calcium channel blockers, beta\-blockers and neprilysin inhibitors;
  • •\-Use of drugs acting on the renin\-angiotensin\-aldosterone system other than ACEI/ARB, e.g. aliskiren.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Angiotensin Converting Enzyme (ACE) inhibition for the preservation of renal function and patient survival in kidney transplantatioChronic kidney disease in renal transplant patientsUrological and Genital DiseasesChronic kidney disease
ISRCTN78129473Ottawa Hospital Research Institute (OHRI) (Canada) - formerly Ottawa Health Research Institute528
Active, not recruiting
Phase 1
Angiotensin Converting Enzyme Inhibitor (ACE) Induced AngioedemaBERINERTRandomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced AngioedemaAngiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and neck region. These can lead to severe dyspnoea and the need for intubation and are thought to be bradykinin mediated. Up until now there is no study-evaluated conservative therapeutic concept for the treatment of these patients.MedDRA version: 18.1Level: HLTClassification code 10002425Term: AngioedemasSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2012-001670-28-DEMedizinische Fakultät der Technischen Universität München52
Active, not recruiting
Not Applicable
ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuriaThe primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documentedMedDRA version: 9.1Level: SOCClassification code 10038359Term: Renal and urinary disorders
EUCTR2005-003885-40-ITAZIENDA OSPEDALIERA PROVINCIALE DI LECCO
Completed
Phase 3
The Effect of Angiotensin Convetring Enzyme Inhibitor on the Quality of Life of Non Hospitalized Patients With Cancer Cachexia in Shiraz University ClinicsGastric cancer.Malignant neoplasm of stomach
IRCT2014050511375N3Shiraz University of Midical Sciences40
Completed
Not Applicable
Effect of Angiotensin Converting Enzyme Inhibition (ACEI) on C-Reactive Protein (CRP) Levels: The Ramipril CRP Randomized Evaluation (4R Trial)Healthy volunteers with elevated levels of C-Reactive proteinCirculatory System
ISRCTN31129526Sanofi-Aventis (Canada)400